Andere Sprachen Shanghai Henlius Biotech, Inc.

Aktien

A2PRXP

CNE100003N76

2696

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:20 26.04.2024			% 5 Tage	% 1. Jan.
16,5 ^HKD	+0,98 %		+11,34 %	+18,71 %

26.04.	Krebsmedikament von Shanghai Henlius Biotech erhält grünes Licht von der US FDA	MT
24.04.	Shanghai Henlius Biotech verabreicht ersten Patienten in klinischer Studie zu Fibrose-Medikament in China	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA	26.04.
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China	24.04.
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China	23.04.
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA	18.04.
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity	17.04.
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug	17.04.
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration	17.04.
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08.04.
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints	08.04.
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints	05.04.
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints	05.04.
Shanghai Henlius Biotech Turns to Profit in 2023	22.03.
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug	15.03.
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection	14.03.
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials	13.03.
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration	12.03.
Shanghai Henlius Biotech Expects Record Full-Year Profit	05.03.
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development	04.03.
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shanghai Henlius Biotech, Inc.

Aktien

A2PRXP

CNE100003N76

2696

Andere Sprachen

Filter